Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71) - Endotext - NCBI Bookshelf

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Endotext

Endotext [Internet].

Table 8Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71)

	Placebo			Exenatide 5 mcg bid			Exenatide 10 mcg bid
In combination with:	MET	SFU	MET+ SFU	MET	SFU	MET + SFU	MET	SFU	MET + SFU
ITT population (n)	113	123	247	110	125	245	113	129	241
Mean baseline A1C (%)	8.2	8.7	8.5	8.3	8.5	8.5	8.2	8.6	8.5
Change at week 30 (%)	+0.1	+0.1	+0.2	-0.4^a	-0.5^a	-0.6^b	-0.8^b	-0.9^b	-0.8^b
Proportion achieving A1C ≤ 7% (%)	13	9	9	32^a	33^a	27^b	46^a	41^b	34^b
Mean baseline body weight (kg)	99.9	99.1	99.1	100.0	94.9	96.9	100.9	95.2	98.4
Change at week 30 (kg)	-0.3	-0.6	-0.9	-1.6	-0.9	-1.6^a	-2.8^b	-1.6^a	-1.6^a
^a P ≤ 0.05 vs placebo^b P ≤ 0.0001 vs placebo

From: Treatment for Type 2 Diabetes

Copyright © 2000-2024, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Views

Cite this Page
Juang PS, Henry RR. Treatment for Type 2 Diabetes. [Updated 2013 Sep 4]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71)

Similar articles in PubMed

Review Type II diabetes mellitus.[Adv Intern Med. 1998]
Review Type II diabetes mellitus.
Edelman SV. Adv Intern Med. 1998; 43:449-500.
Review Inhibition of glucagon secretion.[Adv Pharmacol. 2005]
Review Inhibition of glucagon secretion.
Young A. Adv Pharmacol. 2005; 52:151-71.
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.[Diabetes Res Clin Pract. 2002]
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, et al. Diabetes Res Clin Pract. 2002 Jan; 55(1):65-85.
Beta-cell function and mass in type 2 diabetes.[Dan Med Bull. 2009]
Beta-cell function and mass in type 2 diabetes.
Larsen MO. Dan Med Bull. 2009 Aug; 56(3):153-64.
Review The Role of TRP Channels in the Pancreatic Beta-Cell.[Neurobiology of TRP Channels. ...]
Review The Role of TRP Channels in the Pancreatic Beta-Cell.
Philippaert K, Vennekens R. Neurobiology of TRP Channels. 2017

See reviews...See all...

Recent Activity

Clear Turn Off Turn On

Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with M...
Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71) - Endotext

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on